1.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

2.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

3.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

4.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

5.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

6.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

7.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

8.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

9.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

1.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

2.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

3.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

4.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

5.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

6.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

7.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

8.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

9.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

1.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

2.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

3.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

4.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

5.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

6.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

7.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

8.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

9.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

1.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

2.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

3.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

4.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

5.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

6.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

7.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

8.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

9.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

1.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

2.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

3.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

4.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

5.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

6.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

7.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

8.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

9.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

1.

Genetic Variation in RIN3 in the Belgian Population Supports Its Involvement in the Pathogenesis of Paget's Disease of Bone and Modifies the Age of Onset.

2.

Genetic Variation in RIN3 in the Belgian Population Supports Its Involvement in the Pathogenesis of Paget's Disease of Bone and Modifies the Age of Onset.

3.

Genetic Variation in RIN3 in the Belgian Population Supports Its Involvement in the Pathogenesis of Paget's Disease of Bone and Modifies the Age of Onset.

4.

Genetic Variation in RIN3 in the Belgian Population Supports Its Involvement in the Pathogenesis of Paget's Disease of Bone and Modifies the Age of Onset.

5.

Genetic Variation in RIN3 in the Belgian Population Supports Its Involvement in the Pathogenesis of Paget's Disease of Bone and Modifies the Age of Onset.

6.

Genetic Variation in RIN3 in the Belgian Population Supports Its Involvement in the Pathogenesis of Paget's Disease of Bone and Modifies the Age of Onset.

7.

Genetic Variation in RIN3 in the Belgian Population Supports Its Involvement in the Pathogenesis of Paget's Disease of Bone and Modifies the Age of Onset.

8.

Genetic Variation in RIN3 in the Belgian Population Supports Its Involvement in the Pathogenesis of Paget's Disease of Bone and Modifies the Age of Onset.

9.

Genetic Variation in RIN3 in the Belgian Population Supports Its Involvement in the Pathogenesis of Paget's Disease of Bone and Modifies the Age of Onset.

1.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

2.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

3.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

4.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

5.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

6.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

7.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

8.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

9.

Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.

1.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

2.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

3.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

4.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

5.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

6.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

7.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

8.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

9.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

1.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

2.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

3.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

4.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

5.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

6.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

7.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

8.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

9.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

1.

Sensitization to isobornyl acrylate in a tertiary Belgian hospital.

2.

Sensitization to isobornyl acrylate in a tertiary Belgian hospital.

3.

Sensitization to isobornyl acrylate in a tertiary Belgian hospital.

4.

Sensitization to isobornyl acrylate in a tertiary Belgian hospital.

5.

Sensitization to isobornyl acrylate in a tertiary Belgian hospital.

6.

Sensitization to isobornyl acrylate in a tertiary Belgian hospital.

7.

Sensitization to isobornyl acrylate in a tertiary Belgian hospital.

8.

Sensitization to isobornyl acrylate in a tertiary Belgian hospital.

9.

Sensitization to isobornyl acrylate in a tertiary Belgian hospital.